Inozyme Pharma, Inc. (INZY)

Inozyme Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	20.93	34.9	33.27	23.32	28.39	31.74
Short-Term Investments	145.54	154	94.95	88.49	119.66	15.53
Cash & Cash Equivalents	166.46	188.9	128.22	111.8	148.05	47.26
Cash Growth	26.80%	47.32%	14.69%	-24.48%	213.26%	9.50%
Other Current Assets	7.86	7.35	3.17	3.54	2.93	0.2
Total Current Assets	174.32	196.25	131.39	115.34	150.98	47.46
Property, Plant & Equipment	2.31	2.59	3.64	4.44	2.65	0.3
Long-Term Investments	0	0	0	0	12.2	0
Other Long-Term Assets	0.31	2.01	4.16	3.76	3.54	0.19
Total Long-Term Assets	2.62	4.6	7.8	8.2	18.38	0.48
Total Assets	176.94	200.85	139.2	123.54	169.36	47.94
Accounts Payable	2.17	1.17	2.54	2.39	3.07	0.9
Current Debt	0.93	0.91	0.82	0.73	0	0
Other Current Liabilities	9.31	12.61	11.36	8.51	6.9	2.34
Total Current Liabilities	12.41	14.69	14.72	11.63	9.97	3.24
Long-Term Debt	45.7	45.68	5.96	2.64	1.29	0
Other Long-Term Liabilities	0	0	0.12	0	0	0
Total Long-Term Liabilities	45.7	45.68	6.09	2.64	1.29	0
Total Liabilities	58.11	60.37	20.8	14.27	11.26	3.24
Total Debt	46.64	46.59	6.78	3.37	1.29	0
Debt Growth	74.92%	587.40%	101.07%	161.93%	-	-
Retained Earnings	-309.28	-285.93	-214.76	-147.7	-91.08	-34.65
Comprehensive Income	-0.11	0.04	-0.21	0.02	0	0.01
Shareholders' Equity	118.84	140.48	118.39	109.27	158.1	-33.22
Net Cash / Debt	119.83	142.31	121.44	108.43	146.76	47.26
Net Cash / Debt Growth	14.53%	17.18%	12.00%	-26.12%	210.53%	9.50%
Net Cash Per Share	1.94	2.75	3.22	4.60	13.30	39.95
Working Capital	161.92	181.56	116.68	103.71	141.01	44.22
Book Value Per Share	1.92	2.71	3.13	4.64	14.32	-28.08

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).